These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16527885)

  • 1. Influence of sample type and storage conditions on soluble CD40 ligand assessment.
    Weber M; Rabenau B; Stanisch M; Elsaesser A; Mitrovic V; Heeschen C; Hamm C
    Clin Chem; 2006 May; 52(5):888-91. PubMed ID: 16527885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes.
    Weber M; Rabenau B; Stanisch M; Nef HM; Möllmann H; Elsässer A; Mitrovic V; Heeschen C; Hamm C
    Thromb Res; 2007; 120(6):811-4. PubMed ID: 17337289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation.
    Ivandic BT; Spanuth E; Haase D; Lestin HG; Katus HA
    Clin Chem; 2007 Jul; 53(7):1231-4. PubMed ID: 17495016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different behaviour of soluble CD40L concentrations can be reflected by variations of preanalytical conditions.
    Wenzel F; Baertl A; Zimmermann N; Hohlfeld T; Giers G; Oldenburg J; Assert R
    Clin Hemorheol Microcirc; 2008; 39(1-4):417-22. PubMed ID: 18503154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of pre-analytical and analytical factors on soluble CD40L measurements.
    Varo N; Nuzzo R; Natal C; Libby P; Schönbeck U
    Clin Sci (Lond); 2006 Nov; 111(5):341-7. PubMed ID: 16856875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum.
    Lengellé J; Panopoulos E; Betsou F
    Cytokine; 2008 Nov; 44(2):275-82. PubMed ID: 18851919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease.
    Türker S; Güneri S; Akdeniz B; Ozcan MA; Baris N; Badak O; Kirimli O; Yüksel F
    Am J Cardiol; 2006 Jan; 97(2):198-202. PubMed ID: 16442363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16.
    Olenchock BA; Wiviott SD; Murphy SA; Cannon CP; Rifai N; Braunwald E; Morrow DA
    J Thromb Thrombolysis; 2008 Oct; 26(2):79-84. PubMed ID: 17917707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk.
    Ahn ER; Lander G; Jy W; Bidot CJ; Jimenez JJ; Horstman LL; Ahn YS
    Thromb Res; 2004; 114(2):143-8. PubMed ID: 15306157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum sST2 and sCD40L values in patients with microvascular angina.
    Aslan G; Polat V; Bozcali E; Opan S; Çetin N; Ural D
    Microvasc Res; 2019 Mar; 122():85-93. PubMed ID: 30502363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers.
    Verma S; Wang CH; Li SH; Lonn E; Charbonneau F; Title LM; Anderson TJ;
    Atherosclerosis; 2005 Oct; 182(2):361-5. PubMed ID: 16159609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease.
    Mason PJ; Chakrabarti S; Albers AA; Rex S; Vitseva O; Varghese S; Freedman JE
    Am J Cardiol; 2005 Nov; 96(10):1365-9. PubMed ID: 16275179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?
    Lim HS; Tayebjee MH; Tan KT; Patel JV; Macfadyen RJ; Lip GY
    Thromb Res; 2008; 122(3):307-13. PubMed ID: 18054068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.
    Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
    Kidney Int Suppl; 2008 Dec; (111):S60-3. PubMed ID: 19034329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Changes and relations of soluble plasma CD40L and matrix metalloproteinase-9 levels in patients with coronary heart disease].
    Li J; Zhao SP; Peng DQ; Zhou HN
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):517-20. PubMed ID: 16137036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of plasma soluble CD40 ligand levels in patients with nasopharyngeal carcinoma.
    Zhao P; Fang WJ; Chai L; Ruan J; Zheng Y; Jiang WQ; Lin S; Zhou SH; Zhang ZL
    Clin Chim Acta; 2015 Jul; 447():66-70. PubMed ID: 26032866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
    Choudhury A; Chung I; Panja N; Patel J; Lip GYH
    Chest; 2008 Sep; 134(3):574-581. PubMed ID: 18641098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum soluble CD40L level and its application in coronary heart disease].
    Li J; Peng DQ; Zhao SP
    Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):611-4. PubMed ID: 15804073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
    Mälarstig A; Lindahl B; Wallentin L; Siegbahn A
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1667-73. PubMed ID: 16627810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.